Literature DB >> 6176998

Identification of Epstein-Barr virus strain differences with monoclonal antibody to a membrane glycoprotein.

L F Qualtiere, R Chase, B Vroman, G R Pearson.   

Abstract

Two monoclonal antibodies directed against Epstein--Barr virus (EBV)-induced membrane antigens (MA) were isolated in this study. On of the monoclonal antibodies, designated 2F5.6, was an IgG2 which, as detected by membrane and fixed cell immunofluorescence, reacted with MA-positive lymphoblastoid cell lines that produced transforming EBV but not with the MA-positive P3HR-1 cell line that produced the lytic, nontransforming strain of this virus. This antibody precipitated the Mr 320,000/350,000 glycoprotein from B-95 virus infected cultures and the Mr 300,000 and 220,000/250,000 glycoproteins from Raji cells superinfected with P3HR-1 virus but did not precipitate any of these EBV-specific glycoproteins from the P3HR-1 cell line. In contrast, the second monoclonal antibody, IgM designated B10.3, reacted with all virus-producing cell lines including the P3HR-1 cell line. The identity of the glycoprotein that serves as the target for this antibody is still unknown. Neither antibody had neutralizing activity against the B-95 or P3HR-1 strain of EBV. These results indicated that the 2F5.6 monoclonal antibody was directed against an antigenic determinant on the major membrane glycoprotein which is common to transforming strains of EBV but absent from the lytic P3HR-1 stain whereas the B10.3 monoclonal antibody was directed against a group-specific EBV-induced membrane determinant.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6176998      PMCID: PMC345797          DOI: 10.1073/pnas.79.2.616

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Biological differences between Epstein-Barr virus (EBV) strains with regard to lymphocyte transforming ability, superinfection and antigen induction.

Authors:  J Menezes; W Leibold; G Klein
Journal:  Exp Cell Res       Date:  1975-05       Impact factor: 3.905

2.  Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens.

Authors:  G R Pearson; T W Orr
Journal:  J Natl Cancer Inst       Date:  1976-03       Impact factor: 13.506

3.  Epstein-Barr virus: transformation, cytopathic changes, and viral antigens in squirrel monkey and marmoset leukocytes.

Authors:  G Miller; T Shope; H Lisco; D Stitt; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1972-02       Impact factor: 11.205

4.  Early events in transformation of human cord leukobytes by Epstain-Barr virus: induction of DNA synthesis, mitosis and the virus-associated nuclear antigen synthesis.

Authors:  T Aya; T Osato
Journal:  Int J Cancer       Date:  1974-09-15       Impact factor: 7.396

5.  Production of antigens associated with Epstein-Barr virus in experimentally infected lymphoblastoid cell lines.

Authors:  G R Pearson; G Henle; W Henle
Journal:  J Natl Cancer Inst       Date:  1971-06       Impact factor: 13.506

6.  Host cell macromolecular synthesis in cells containing EBV-induced early antigens, studied by combined immunofluorescence and radioautography.

Authors:  L Gergely; G Klein; I Ernberg
Journal:  Virology       Date:  1971-07       Impact factor: 3.616

7.  Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines.

Authors:  B M Reedman; G Klein
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

8.  Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference.

Authors:  G Miller; J Robinson; L Heston; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1974-10       Impact factor: 11.205

9.  Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line.

Authors:  Y Hinuma; M Konn; J Yamaguchi; D J Wudarski; J R Blakeslee; J T Grace
Journal:  J Virol       Date:  1967-10       Impact factor: 5.103

10.  Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.

Authors:  W Henle; G Henle; B A Zajac; G Pearson; R Waubke; M Scriba
Journal:  Science       Date:  1970-07-10       Impact factor: 47.728

View more
  14 in total

1.  Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.

Authors:  M Khyatti; P C Patel; I Stefanescu; J Menezes
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

2.  Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.

Authors:  M Rowe; A L Lear; D Croom-Carter; A H Davies; A B Rickinson
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

3.  Characterization of a major protein with a molecular weight of 160,000 associated with the viral capsid of Epstein-Barr virus.

Authors:  B Vroman; J Luka; M Rodriguez; G R Pearson
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

4.  Identification of the Epstein-Barr virus gp85 gene.

Authors:  T Heineman; M Gong; J Sample; E Kieff
Journal:  J Virol       Date:  1988-04       Impact factor: 5.103

5.  Identification and characterization of a cellular protein that cross-reacts with the Epstein-Barr virus nuclear antigen.

Authors:  J Luka; T Kreofsky; G R Pearson; K Hennessy; E Kieff
Journal:  J Virol       Date:  1984-12       Impact factor: 5.103

6.  An Epstein-Barr virus DNA fragment encodes messages for the two major envelope glycoproteins (gp350/300 and gp220/200).

Authors:  M Hummel; D Thorley-Lawson; E Kieff
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

7.  Identification of polypeptide components of the Epstein-Barr virus early antigen complex with monoclonal antibodies.

Authors:  G R Pearson; B Vroman; B Chase; T Sculley; M Hummel; E Kieff
Journal:  J Virol       Date:  1983-07       Impact factor: 5.103

8.  Two major outer envelope glycoproteins of Epstein-Barr virus are encoded by the same gene.

Authors:  C Beisel; J Tanner; T Matsuo; D Thorley-Lawson; F Kezdy; E Kieff
Journal:  J Virol       Date:  1985-06       Impact factor: 5.103

9.  Purified Epstein-Barr virus Mr 340,000 glycoprotein induces potent virus-neutralizing antibodies when incorporated in liposomes.

Authors:  J R North; A J Morgan; J L Thompson; M A Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

10.  Membrane antigen on Epstein--Barr virus-infected human B cells recognized by a monoclonal antibody.

Authors:  S F Slovin; D M Frisman; C D Tsoukas; I Royston; S M Baird; S B Wormsley; D A Carson; J H Vaughan
Journal:  Proc Natl Acad Sci U S A       Date:  1982-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.